Welcome to our searchable resource and literature collection on safer supply and related topics.

Found a broken link? Links do move around, so if you find one here that's broken, please let us know through the Contact form.


This study aims to better understand the impact of legislation aimed to restrict opioid prescribing on patients and providers.

Original research | 2022
Policy/Regulatory, Hesitancy of prescribers , About prescribers

Le présent document d’information offre un aperçu des enjeux émergents ainsi que des défis particuliers que pose la COVID-19 sur le plan de la santé mentale et de l’usage de

Rapport | 2022
la santé mentale, les services de santé numériques, rural / éloigné

This policy brief provides an overview of the developing issues and unique mental health and substance use challenges that COVID-19 poses for rural and remote communities.

Report | 2022
Mental health, Digital health, Rural/remote

To explore the implementation and effectiveness of the British Columbia, Canada, risk mitigation guidelines among people who use drugs, focusing on how experiences with the illicit drug supply shap

Original research | 2022
Safer supply, Evidence base, Illegal drugs, About PWUD

To describe current approaches in treatment of opioid use disorder (OUD) within Canadian psychosocial outpatient, day, and residential addiction treatment programs, with an emphasis on the use of o

Original research | 2022
About prescribers, Substitution, Transitions in care/treatment
Guide or handbook | 2022
Substitution, Clinical guidance, Policy/Regulatory, Wrap-around services, About prescribers, Hesitancy of prescribers , Transitions in care/treatment

Longitudinal studies suggest that low clinical insight could be linked to more relapse. However, association with successful quit attempts remains unknown.

Original research | 2022
About PWUD, Transitions in care/treatment, Outcomes

Following user-centered development and testing phases, a multi-feature smartphone application called HOPE (Heal. Overcome. Persist.

Original research | 2022
About PWUD, Digital health, Outcomes

Few persons who initiate MOUD are retained on treatment, thus it is critical to identify factors associated with retention.

Original research | 2022
Substitution, About PWUD, Outcomes

This study examined metropolitan and rural differences regarding concerns about opioid misuse and support for different strategies to reduce opioid use disorder risk in areas not designated as high

Original research | 2022
Rural/remote, Illegal drugs

This study aimed to capture people who use drugs’ (PWUD) lived experiences to understand motivations underlying fentanyl test strip uptake, ongoing use, and actions after testing.

Original research | 2022
Harm reduction, About PWUD, Illegal drugs, Drug checking

Examine 30-day measures of substance use, overdose experiences, and number of “protected” opioid use events, defined as involving naloxone and the presence of another person who could administer it

Original research | 2022
Harm reduction, About PWUD, Social benefits, Overdose, Illegal drugs, Equity

This study aims to understand the implications that this has for the life circumstances and risk management of people who use drugs in areas of low access.

Original research | 2022
Harm reduction, Barriers and enablers, About PWUD, Stigma, Illegal drugs

This rapid review sought to summarize the retention rates reported by randomized controlled trials (RCTs) and controlled observational study designs that compared methadone to buprenorphine (or bup

Lit review | 2021
Substitution, Outcomes, About PWUD

Assess whether supervised consumption clients use methadone, or whether their use of methadone prevents opioid overdose.

Thesis | 2022
Substitution, About PWUD, SCS/OPS, Overdose, Illegal drugs

To examine potentially unsafe tapering and discontinuation among dosage changes in opioid prescriptions dispensed to US patients on high-dose long-term opioid therapy.

Original research | 2022
About PWUD, Withdrawal

We aimed to evaluate the association between benzodiazepine use in the first trimester of pregnancy and the risk of major congenital malformations.

Original research | 2022
Sex/Gender , Outcomes, Parents/caregivers

Among recipients of opioid agonist therapy (OAT) in Ontario, Canada, early in the COVID-19 pandemic, was there an association between dispensing of increased take-home doses and treatment retention

Original research | 2022
Policy/Regulatory, Substitution, Overdose, Evidence base
Revue de la littérature | 2022
À propos des personnes qui utilisent des drogues, l'équité

Refine Your Search